• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Ascendis Pharma ADR (NQ: ASND )

    124.81 +1.99 (+1.62%)
    Streaming Delayed Price Updated: 11:51 AM EDT, Nov 1, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about Ascendis Pharma ADR

    3 Oversold Stocks with Big RSI Rebound Potential
    Everybody loves finding a bargain or getting a good deal, and it's no different when it comes to stocks. The RSI indicator is a great way to find them. 
    Via MarketBeat
    Topics Economy
    Exposures Interest Rates
    Royalty Pharma and Ascendis Pharma Enter Into $150 Million Royalty Funding Agreement
    Proceeds to support continued development and commercialization of Endocrine Rare Disease products, including the Yorvipath U.S. commercial launch, and general corporate purposes 
    From Royalty Pharma plc
    Via GlobeNewswire
    Royalty Pharma and Ascendis Pharma Enter Into $150 Million Royalty Funding Agreement
    From Royalty Pharma plc
    Via GlobeNewswire
    Bragar Eagel & Squire, P.C. Is Investigating Ascendis, Alvotech, Shift4, and Waldencast and Encourages Investors to Contact the Firm
    From Bragar Eagel & Squire
    Via GlobeNewswire
    Bragar Eagel & Squire, P.C. Is Investigating Zai Lab, Hayward, Ascendis, and Alvotech and Encourages Investors to Contact the Firm
    From Bragar Eagel & Squire
    Via GlobeNewswire
    NASDAQ: ASND Investor Alert: Investigation over Potential Wrongdoing at Ascendis Pharma A/S
    San Diego, CA -- (SBWIRE) -- 06/20/2023 -- Certain directors of Ascendis Pharma A/S are under investigation over potential breaches of fiduciary duties by certain directors. 
    Via SBWire
    Bragar Eagel & Squire, P.C. Is Investigating C3.ai, Ascendis, Alvotech, and Shift4 and Encourages Investors to Contact the Firm
    From Bragar Eagel & Squire
    Via GlobeNewswire
    Bragar Eagel & Squire, P.C. Is Investigating Fox, Ascendis, and Shift4 and Encourages Investors to Contact the Firm
    From Bragar Eagel & Squire
    Via GlobeNewswire
    NASDAQ: ASND Shareholder Notice: Investigation over Possible Securities Laws Violations by Ascendis Pharma A/S
    San Diego, CA -- (SBWIRE) -- 04/17/2023 -- Ascendis Pharma A/S is under investigation over potential securities laws violations in connection with certain financial statements. 
    Via SBWire
    ROSEN, NATIONALLY REGARDED INVESTOR COUNSEL, Encourages Ascendis Pharma Investors to Inquire About Securities Class Action Investigation - ASND
    Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
    Via NewMediaWire
    Exposures Product Safety
    ASCENDIS ALERT: Bragar Eagel & Squire, P.C. is Investigating Ascendis Pharma A/S on Behalf of Ascendis Stockholders and Encourages Investors to Contact the Firm
    From Bragar Eagel & Squire, P.C.
    Via Business Wire
    Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Ascendis Pharma A/S (ASND) Investigation
    From Bronstein, Gewirtz & Grossman, LLC
    Via Business Wire
    INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Ascendis Pharma A/S and Encourages Investors with Losses to Contact the Firm
    From The Schall Law Firm
    Via Business Wire
    INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Ascendis Pharma A/S and Encourages Investors with Losses to Contact the Firm
    From The Schall Law Firm
    Via Business Wire
    ASND LOSS ALERT: ROSEN, NATIONAL TRIAL LAWYERS, Encourages Ascendis Pharma Investors to Inquire About Securities Class Action Investigation – ASND
    From The Rosen Law Firm, P.A.
    Via Business Wire
    Johnson & Johnson: Taking The Bull By The Horns?
    Johnson & Johnson is rushing toward a patent cliff but a new shelf offering registration suggests itis gearing up for acquisitions. 
    Via MarketBeat
    Topics Intellectual Property Regulatory Compliance
    Exposures Intellectual Property Legal Regulatory
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.